Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 losmapimod study in facioscapulohumeral muscular dystrophy
2022-000389-16Phase 3Active
- Sponsor
- Fulcrum Therapeutics
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in facioscapulohumeral muscular dystrophy (FSHD) comparing Losmapimod with Placebo (2 arms). Primary endpoint: Change from baseline in total RSA Q1-Q5 with 500 g wrist weight in dominant arm at Week 48. Started May 2022; status: active.
02
Drugs
losmapimod
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on 2022-000389-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000389-16.